Further pharmacogenetic analyses had identified several variants in CACNA1C were associated with the efficacy of antihypertensive effects of CCBs in hypertensive patients among different populations. [10] [11] [12] Therefore, we presumed that the CACNA1A and CACNA1C genes had crucial effects on the regulation of BP. However, single marker and aggregate associations of CACNA1A and CACNA1C genes with BP-related phenotypes were not investigated in a cohort study. Furthermore, very few of these studies have been conducted in Han Chinese population. Thus, we aimed to examine the relationships of CACNA1A and CACNA1C with BP changes over time and incident hypertension by using both single-marker and gene-based association analyses. The current study was conducted in a large, homogeneous sample of Han Chinese participants from the Genetic Epidemiology Network of Salt Sensitivity (GenSalt) follow-up study.
METHODS

Study population
The GenSalt study was conducted among Han Chinese population in 6 rural villages in Northern China from 2003 to 2005. Details of the study design and methods have been published elsewhere. 13 Briefly, a community-based BP screening was conducted among persons aged 18-60 years in the study villages to identify potential probands and their families. Those with mean systolic BP (SBP) of 130-160 mm Hg and/or diastolic BP (DBP) of 85-100 mm Hg and no use of antihypertensive medications, as well as their parents, spouses, siblings, and offspring were recruited for the study. Individuals were excluded if they had stage 2 hypertension, secondary hypertension, a history of cardiovascular disease or diabetes, pregnancy, heavy alcohol consumption, or low-sodium diet lifestyle.
Institutional review boards at all of the participating institutions approved the GenSalt study. Written informed consents were obtained from all participants.
GenSalt baseline data collection
A standard questionnaire was administered by trained investigators at the baseline examination to collect information on demographic characteristics, personal and family medical history, and lifestyle risk factors. Three morning BP measurements were obtained according to a standard protocol on each of the 3 days of baseline observation by trained and certified observers using a random-zero sphygmomanometer. 14 BP was measured from the right arm of participants in the sitting position after 5 minutes of rest. In addition, participants were advised to avoid alcohol, cigarette smoking, coffee/tea, and exercise for at least 30 minutes prior to their BP measurements. The average of the 9 BP readings was used for analysis. Body weight and height were measured twice in light indoor clothing without shoes. Body mass index (BMI) was calculated as kilograms per square meter (kg/m 2 ).
GenSalt follow-up
The GenSalt study participants were re-examined from 2008 to 2009 and 2011 to 2012 in the GenSalt follow-up study. Three BP measurements were obtained in the morning during each of 3 days of follow-up visits according to the same protocol used in the GenSalt study. Hypertension was defined as SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg or the use of antihypertensive medications.
Among 1,906 eligible participants from 633 families who completed the baseline examination, 117 individuals were missing BP information at both of the follow-up visits, and another 21 individuals were missing genotype data. The remaining 1,768 participants (92.8%) were eligible for our analysis.
Genotype data and quality control
The genes CACNA1A and CACNA1C were selected based on their potential effect on BP regulation. Within the 2 candidate genes (±5,000-bp flanking regions), 369 singlenucleotide polymorphisms (SNPs) were genotyped on the Affymetrix 6.0 platform (Affymetrix, Santa Clara, CA). Quality control, including checks of Mendelian consistency, genotyping call rate, minor allele frequency, and HardyWeinberg equilibrium, was performed using Plink software (version 1.05; Dr Sean Purcell, http://pngu.mgh.harvard. edu/~purcell/plink/). 15 Sixty-two SNPs were excluded because of minor allele frequency < 1%, genotyping call rate < 95%, or deviation from the Hardy-Weinberg equilibrium after correction for multiple testing. After quality control, we selected tag-SNPs with pairwise r 2 thresholds of less than 0.9 using Haploview software (version 4.2, http://www. brod.mit.deu/mpg/haploview/). A total of 176 tag-SNPs in CACNA1A and CACNA1C were included in the current analysis. Characteristics of these SNPs were presented in Supplementary Table 1 .
Statistical analysis
The characteristics of study participants were presented as means for continuous variables and as frequencies (percentages) for categorical variables. The additive associations between genotyped SNPs and longitudinal SBP and DBP changes were analyzed using mixed-effect linear regression models to accommodate the longitudinal, family-based design of the GenSalt study. 16, 17 Autoregressive and compound symmetry covariance matrices were used to account for the correlations of repeated measurements within individuals and of individuals within families, respectively. To evaluate the significance of the association of each SNP with longitudinal BP change, a genotype by follow-up time interaction term and the main effects of these variables were included in the models. Models were additionally adjusted for the fixed effects of age, gender, and BMI using the PROC MIXED procedure in SAS (version 9.3; SAS Institute, Cary, NC). The mixed-effect model we used was as follows:
In the formula, β 0 was the mean after accounting for covariates, genetic effects, and the interaction term. The terms age ij , gender ij , and BMI ij represented baseline age, gender, and BMI of the ith individual in the jth family, respectively. SNP ij modeled the genetic main effect, where the genotype was coded under an additive model. Time ijk was the follow-up years since baseline for the ith individual in the jth family at the kth visit. The seventh term represents the linear interaction between genetic effects and follow-up time. The random effects terms a ijk and b ijk account for the correlation among individuals in the same family as well as the correlation of repeated measures among individuals nested within families. The last term stands for residual. To account for the effects of antihypertensive medication, we conducted these analyses using imputed BP levels for participants taking antihypertensive medication by adding 10 and 5 mm Hg to original SBP and DBP values, respectively. 18 A sensitivity analysis was also conducted after excluding those participants taking antihypertensive treatment in the month prior to visit. Regarding the analyses of incident hypertension, 173 participants with hypertension at baseline were excluded. The additive association of SNPs with hypertension incidence was evaluated using a generalized linear mixed model. 19 Age, sex, BMI, and follow-up time were adjusted in multivariable analysis using the PROC GLIMMIX procedure in SAS.
Gene-based analysis is an approach that would evaluate the association between a trait and a candidate gene. The truncated product method, which combines P values from single-marker association of each candidate gene with longitudinal BP changes and hypertension incidence, was used to conducted gene-based analysis as described previously. 17 The P values for the genotype by follow-up time interaction term were used for analyses of longitudinal BP changes, while the P values of the genotype term were used for hypertension incidence analyses. The truncation point was set as τ = 0.05, and the P value for truncated product method was estimated through 100,000 simulations. Sensitivity analyses were conducted after excluding the most significant SNP identified in single-marker analyses within a gene to examine their influence on the gene-based analysis. Gene-based analysis was performed using R software (version 3.2.0; http://www.r-project.org).
Bonferroni correction was used for adjustment of multiple testing. The α threshold for single-maker analysis and gene-based analysis was 2.84 × 10 −4 (0.05/176) and 0.025 (0.05/2), respectively.
RESULTS
The characteristics of 1,768 participants during the initial and 2 follow-up interviews were summarized in Table 1 . On average, participants were 39.0 years of age, had a BMI of 23.4 kg/m 2 , and had mean SBP and DBP of 116.9 and 73.8 mm Hg at baseline, respectively. Among the baseline 1,768 participants, 52.3% were male. During a mean followup of 7.2 years, 512 (32.1%) participants developed hypertension, and mean SBP and DBP of participants increased by 12.2 and 8.4 mm Hg, respectively. Figure 1 displays the associations of 176 tag-SNPs in CACNA1A and CACNA1C with BP changes and hypertension incidence. Marker rs8182538 in CACNA1A was significantly associated with longitudinal change in DBP after Bonferroni correction (P interaction = 9.9 × 10 −5 ). Although no SNP showed significant association with SBP change overtime or hypertension incidence after adjustment for multiple testing, SNP rs8182538 achieved nominal significance for longitudinal SBP change. Sensitivity analyses excluding those participants taking antihypertensive treatment from the analyses of BP changes revealed similar results (data not shown).
The average change in BP per year and odds ratios for hypertension incidence according to genotypes of significant SNP is shown in Table 2 . For CACNA1A marker rs8182538, each copy of the minor T allele was associated with larger increases in DBP, with mean DBP increases of 0.85, 1.03, and 1.19 mm Hg for genotypes C/C, C/T, and T/T, respectively. Similar trends were found for SBP changes and odds ratios for hypertension incidence.
Findings of gene-based analysis are presented in Table 3 . Genetic variation in CACNA1A and CACNA1C was found to be associated with DBP and SBP changes over time after Bonferroni correction, respectively (P = 2.0 × 10 −5 for CACNA1A and P = 1.4 × 10 −4 for CACNA1C). No genetic variation in CACNA1A and CACNA1C was significantly associated with incident hypertension. Sensitivity analyses removing the most significant SNP within each gene (rs8182538 in CACNA1A and rs758116 in CACNA1C) also identified significant associations of CACNA1A and CACNA1C with DBP and SBP changes, respectively (P = 3.5 × 10 −4 for CACNA1A and P = 7.1 × 10 −4 for CACNA1C).
DISCUSSION
To our best knowledge, the current study is the first candidate gene study to investigate the association between CACNA1A and CACNA1C genes with longitudinal BP changes and hypertension incidence in the Chinese population. One marker of the CACNA1A, rs8182538, was found to be significantly associated with DBP change over time after Bonferroni correction. Compared to the major allele, each copy of the minor allele of marker rs8182538 predicted larger increase of DBP over an average duration of 7.2 years of follow-up. Furthermore, the gene-based analysis revealed that both CACNA1A and CACNA1C were significantly associated with DBP and SBP changes over time. These results may help to enhance our knowledge of the genetic mechanisms underlying long-term BP regulation and hypertension development.
VDCCs mediate the influx of Ca 2+ into excitable cells and are also involved in a variety of calcium-dependent processes, including vascular smooth muscle contraction, which was crucial in BP regulation. 6 For example, upregulation of VDCCs expression may contribute to Ca 2+ imbalances and result in hypertension. 7, 8 Tajada et al. 20 found that the increased Ca 2+ influx finally led to abnormal arterial tone due to the increased VDCCs function in hypertensive mice. . Abbreviations: β (SE), average change in BP (standard error) per year according to genotypes; BP, blood pressure; DBP, diastolic BP; genotype (N), sample size across genotypes; GenSalt, Genetic Epidemiology Network of Salt Sensitivity; HTN, hypertension; OR, odds ratio; P interaction , P value for genotype by follow-up time interactions; position, GRCh37.p8; SBP, systolic BP; SNP, single-nucleotide polymorphism.
a The sample size for analysis of HTN incidence is 1,595 after excluding hypertensive subjects at baseline, and the numbers of subjects are 481, 811, and 303 for genotypes C/C, C/T, and T/T, respectively. Table 3 . Gene-based associations of CACNA1A and CACNA1C with BP changes and hypertension incidence Moreover, potential interaction of VDCCs expression and RhoA and ERK/p38 mitogen-activated protein kinase pathways could affect the phenotype of vascular smooth muscle cell, 21 which essentially participate in hypertension mechanism. VDCCs are multisubunit complexes, and the channel activity is directed by the pore-forming alpha-1 subunit. CACNA1A and CACNA1C genes encode alpha-1a and alpha1c subunits, respectively, which serve as targets of CCBs.
The present study provides the first evidence of association of CACNA1A marker rs8182538 with BP changes over time. Participants with genotypes C/C, C/T, and T/T had mean DBP increases of 0.85, 1.03, and 1.19 mm Hg, respectively. Similar trends of SBP increases were also shown as 1.35, 1.55, and 1.61 mm Hg for C/C, C/T, and T/T, respectively. This marker is located in an intronic region of CACNA1A without known functional relevance. A large study involving 86,588 participants found nominal evidence of association of CACNA1A marker rs1985579 polymorphisms with BP traits. 9 Unfortunately, neither rs1985579 nor its proxy was genotyped by our study. By using gene-based analysis, we found that CACNA1A was significantly associated with longitudinal DBP change. This finding remained even after removal of rs8182538, revealing that gene-based analysis was not only driven by the observed single-marker association. It was worth pointing out that there might be more than 1 variant associated with BP changes in the CACNA1A, which could not be directly identified by less powerful single-marker analysis. It highlighted the importance of considering both singular and joint effects of variants to elucidate the genetic architecture of complex phenotypes such as longitudinal BP changes. Resequencing followed by functional studies will be warranted to determine the causal variant(s) in CACNA1A that may influence long-term BP regulation and hypertension.
In addition, gene-based analysis found that CACNA1C was significantly associated with SBP change over time, although no single marker in the CACNA1C region showed statistical significant association with BP changes or incident hypertension after correction for multiple testing. Several variants in CACNA1C have been reported to affect the efficacy of CCB in the treatment of hypertension. [10] [11] [12] For instance, a retrospective pharmacogenetic analysis involving 120 Caucasian hypertensive participants found that 3 SNPs in CACNA1C, rs2239128, rs2239050, and rs2238032, had significant associations with antihypertensive outcome, combining to yield a positive treatment outcome of about 15%-80%. 10 In addition, a sequence-proven variant, CACNA1C 527974 G>A, was associated with the antihypertensive effects of L-type dihydropyridine CCBs in Japanese patients with hypertension. 11 However, potential functions of these genetic polymorphisms are still unknown. Furthermore, the human CACNA1C gene, spanning > 500 kb, undergoes extensive mRNA splicing that will bring numerous isoforms with various functions of physiological regulation. 22, 23 Cheng et al. 5 found that the voltage-dependent L-type Ca 2+ N-terminus modified regulation functions of auxiliary subunits through novel alternative splicing at exon 1c in CACNA1C. The variant at exon 1c could generate distinct voltage-dependent Ca 2+ entry in arterial myocytes, which was involved in the regulation of BP. Further deep sequencing is needed to delineate effects of CACNA1C variants on BP regulation and hypertension progression.
The present study had several strengths. To our knowledge, it is the first investigation to examine associations of CACNA1A and CACNA1C genes with BP changes and hypertension incidence in a cohort study, using singlemarker and gene-based analysis. Study attributes such as the recruitment of all Han Chinese participants should make the analysis robust to population stratification. 24 In addition, our study had a high follow-up rate (92.8%) with stringent quality control for genotyping and data collection, including measurements of BP and covariates. However, potential limitations should be addressed. While the genotyping platform used generally provides good coverage of common SNPs across the genome, 25 some rare, low-frequency, and/or structural variants may be missed by our analyses. Further fine mapping of CACNA1A and CACNA1C genes and functional studies will advance our understanding of genetic basis of long-term regulation of BP.
In summary, our study found a significant association of CACNA1A marker rs8182538 with DBP change over time. In addition, the gene-based analysis revealed substantial overall effects of SNPs in the CACNA1A and CACNA1C genes on BP changes among Han Chinese population. The cumulative evidence highlighted the roles of CACNA1A and CACNA1C in BP regulation. Future studies are warranted to confirm these findings and identify causal variants along with their potential functions.
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